Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk, Stephen E. Kurtz, Olga Nikolova, et al.
Cancer Discovery (2019) Vol. 9, Iss. 7, pp. 910-925
Open Access | Times Cited: 285

Showing 1-25 of 285 citing articles:

Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1894
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
Courtney D. DiNardo, Ing Soo Tiong, Anna Quaglieri, et al.
Blood (2020) Vol. 135, Iss. 11, pp. 791-803
Open Access | Times Cited: 536
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia
Shanshan Pei, Daniel A. Pollyea, Annika Gustafson, et al.
Cancer Discovery (2020) Vol. 10, Iss. 4, pp. 536-551
Open Access | Times Cited: 371
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 45-64
Closed Access | Times Cited: 255
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells
Brett M. Stevens, Courtney L. Jones, Daniel A. Pollyea, et al.
Nature Cancer (2020) Vol. 1, Iss. 12, pp. 1176-1187
Open Access | Times Cited: 210
Towards precision medicine for AML
Hartmut Döhner, Andrew H. Wei, Bob Löwenberg
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 577-590
Closed Access | Times Cited: 208
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Ilio Vitale, Federico Pietrocola, Emma Guilbaud, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 5, pp. 1097-1154
Open Access | Times Cited: 207
Emerging agents and regimens for AML
Hongtao Liu
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 183
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Andrew H. Wei, Andrew W. Roberts, Andrew Spencer, et al.
Blood Reviews (2020) Vol. 44, pp. 100672-100672
Open Access | Times Cited: 176
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Haijiao Zhang, Yusuke Nakauchi, Thomas Köhnke, et al.
Nature Cancer (2020) Vol. 1, Iss. 8, pp. 826-839
Open Access | Times Cited: 153
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 142
Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications
Shanliang Zheng, Xingwen Wang, Dong Zhao, et al.
Trends in Cell Biology (2022) Vol. 33, Iss. 4, pp. 312-323
Open Access | Times Cited: 142
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
Evan Cherry, Diana Abbott, Maria L. Amaya, et al.
Blood Advances (2021) Vol. 5, Iss. 24, pp. 5565-5573
Open Access | Times Cited: 127
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
Cancer (2021) Vol. 127, Iss. 20, pp. 3772-3781
Open Access | Times Cited: 117
Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors
Courtney L. Jones, Anagha Inguva, Craig T. Jordan
Cell stem cell (2021) Vol. 28, Iss. 3, pp. 378-393
Open Access | Times Cited: 110
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
Qi Zhang, Bridget Riley‐Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 100
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 24, pp. 5272-5279
Open Access | Times Cited: 99
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 94
CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma
Yiran Chen, Li Li, Jie Lan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 75
Targeting apoptotic pathways for cancer therapy
Xiaobing Tian, Praveen R. Srinivasan, Vida Tajiknia, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 14
Open Access | Times Cited: 22
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea, Maria L. Amaya, Paolo Strati, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4326-4335
Open Access | Times Cited: 143
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia
Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, et al.
Cancer Cell (2020) Vol. 38, Iss. 6, pp. 872-890.e6
Open Access | Times Cited: 120
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortés, et al.
Haematologica (2020) Vol. 106, Iss. 3, pp. 894-898
Open Access | Times Cited: 115
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Eugen Tausch, Christof Schneider, Sandra Robrecht, et al.
Blood (2020) Vol. 135, Iss. 26, pp. 2402-2412
Open Access | Times Cited: 111
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Rachel Thijssen, Sarah T. Diepstraten, Donia M. Moujalled, et al.
Blood (2021) Vol. 137, Iss. 20, pp. 2721-2735
Open Access | Times Cited: 100
Page 1 - Next Page

Scroll to top